Singapur - engleski - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - diphtheria toxoid protein; meningococcal (serogroup a) polysaccharide (monovalent conjugate); meningococcal (serogroup c) polysaccharide (monovalent conjugate); meningococcal (serogroup w-135) polysaccharide (monovalent conjugate); meningococcal (serogroup y) polysaccharide (monovalent conjugate) - injection, solution - 48 microgram (diptheria toxoid quantity is approximate and dependent on the conjugate polysaccharide to protein ratio) - diphtheria toxoid protein 48 mcg/dose (0.5 ml) (diphtheria toxoid quantity is approximate and dependent on the conjugate polysaccharide to protein ratio); meningococcal (serogroup a) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup c) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup w-135) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup y) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml)

Singapur - engleski - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - (acellular pertussis) filamentous haemagglutinin adsorbed (fha); (acellular pertussis) fimbriae type 2 and 3 adsorbed (fim); (acellular pertussis) pertactin adsorbed (prn); (acelullar pertussis) pertussis toxoid adsorbed (pt); diphtheria toxoid adsorbed; tetanus toxoid adsorbed - injection, suspension - 5 micrograms - (acellular pertussis) filamentous haemagglutinin adsorbed (fha) 5 micrograms; (acellular pertussis) fimbriae type 2 and 3 adsorbed (fim) 5 micrograms; (acellular pertussis) pertactin adsorbed (prn) 3 micrograms; (acelullar pertussis) pertussis toxoid adsorbed (pt) 2.5 micrograms; diphtheria toxoid adsorbed 2 lf; tetanus toxoid adsorbed 5 lf

Singapur - engleski - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - purified tetanus toxoid - suspension, sterile - 40 i.u. / 0.5ml dose - purified tetanus toxoid 40 i.u. / 0.5ml dose

Singapur - engleski - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - purified tetanus toxoid - suspension, sterile - ≥ 40 i.u. / 0.5ml dose - purified tetanus toxoid ≥ 40 i.u. / 0.5ml dose

Singapur - engleski - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - hepatitis a virus (inactivated) - injection, suspension - 80 antigen units - hepatitis a virus (inactivated) 80 antigen units

Filipini - engleski - FDA (Food And Drug Administration)

n/a; importer: sanofi pasteur, inc.; distributor: sanofi pasteur, inc. - diphtheria, tetanus, pertussis (whole cell), hepatitis b (idna) and haemophilus influenzae type b conjugate vaccine (adsorbed) - suspension for injection (im) - formulation: each dose (0.5 ml) contains: diphtheria toxoid-> 30 iu tetanus toxoid- > 60 iu bordetella pertussis (whole cell)-> 4u hepatitis b (r-dna) surface antigen-10 ug purified capsular polysaccharide of hib conjugated to 20-40 mcg tetanus toxoid (carrier protein)-10 ug

Europska Unija - engleski - EMA (European Medicines Agency)

sanofi pasteur s.a. - influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.the use of idflu should be based on official recommendations.

Europska Unija - engleski - EMA (European Medicines Agency)

sanofi pasteur europe - influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.the use of intanza should be based on official recommendations.

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi pasteur msd ltd - influenza virus split virion - suspension for injection

Irska - engleski - HPRA (Health Products Regulatory Authority)

sanofi pasteur - rabies virus (inactivated) strain wistar (pm/wi 38-1503-3m) - powder and solvent for suspension for injection in pre-filled syringe - rabies, inactivated, whole virus